Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor (vol 76, pg 89, 2013)

被引：3
|
作者：
Kubitza, D.
Roth, A.
Becka, M.
Alatrach, A.
Halabi, A.
Hinrichsen, H.
Mueck, W.
机构：
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2013年 / 76卷 / 03期
关键词：
D O I：
10.1111/bcp.12215
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：489 / 489
页数：1
相关论文
共 50 条
  • [31] The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol
    Sarich, TC
    Johansson, S
    Schützer, KM
    Wall, U
    Kessler, E
    Teng, RL
    Eriksson, UG
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (04): : 388 - 393
  • [32] No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor
    Wåhlander, K
    Eriksson-Lepkowska, M
    Frison, L
    Fager, G
    Eriksson, UG
    CLINICAL PHARMACOKINETICS, 2003, 42 (08) : 755 - 764
  • [33] Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
    Dorien Groenendaal-van de Meent
    Martin den Adel
    Jan Noukens
    Sanne Rijnders
    Axel Krebs-Brown
    Lyudmila Mateva
    Assen Alexiev
    Marloes Schaddelee
    Clinical Drug Investigation, 2016, 36 : 743 - 751
  • [34] No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor
    Karin Wåhlander
    Maria Eriksson-Lepkowska
    Lars Frison
    Gunnar Fager
    Ulf G. Eriksson
    Clinical Pharmacokinetics, 2003, 42 (8) : 755 - 764
  • [35] Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
    Groenendaal-van de Meent, Dorien
    den Adel, Martin
    Noukens, Jan
    Rijnders, Sanne
    Krebs-Brown, Axel
    Mateva, Lyudmila
    Alexiev, Assen
    Schaddelee, Marloes
    CLINICAL DRUG INVESTIGATION, 2016, 36 (09) : 743 - 751
  • [36] Single dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct factor Xa inhibitor in healthy male subjects.
    Kubitza, D
    Becka, M
    Wensing, G
    Voith, B
    Zuehlsdorf, M
    BLOOD, 2003, 102 (11) : 813A - 813A
  • [37] Partial reversal of the anticoagulant effect of high-dose rivaroxaban - An oral, direct factor Xa inhibitor - by recombinant factor VIIa in rats.
    Tinel, Hanna
    Huetter, Joachim
    Perzborn, Elisabeth
    BLOOD, 2006, 108 (11) : 274A - 274A
  • [38] The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban - An oral, direct factor Xa inhibitor.
    Kubitza, Dagmar
    Becka, Michael
    Mueck, Wolfgang
    Zuehlsdorf, Michael
    BLOOD, 2006, 108 (11) : 271A - 272A
  • [39] Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939) -: An oral, direct, factor Xa inhibitor.
    Halabi, Atef
    Maatouk, Haidar
    Klause, Norbert
    Lufft, Volkmar
    Kubitza, Dagmar
    Zuehlsdorf, Michael
    Becka, Michael
    Mueck, Wolfgang
    Schaefers, Rafael
    Wand, Dominic
    Philipp, Thomas
    Bruck, Heike
    BLOOD, 2006, 108 (11) : 274A - 274A
  • [40] Aliskiren, an oral direct renin inhibitor, has no effect on the pharmacokinetics or pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.
    Huang, H. A.
    Vaidyanathan, S.
    Yeh, C.
    Dieterich, H. A.
    Dole, W. P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S59 - S60
12345